Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.38 |
| ▸ | GLP1R | P43220 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300100 | 0.85 | AGTR1 (0.44) | AGTR1AGTR2TBXA2R | |
| SCHEMBL5103832 | 0.84 | AGTR1 (0.42) | AGTR1AGTR2TBXA2RTP53 | |
| SCHEMBL6304821 | 0.83 | PPARG (0.38) | AGTR1AGTR2TP53ALDH1A1 | |
| SCHEMBL6300107 | 0.82 | AGTR1 (0.41) | AGTR1AGTR2TBXA2RTP53 | |
| SCHEMBL6298925 | 0.81 | AGTR1 (0.40) | AGTR1AGTR2TBXA2RTP53 | |
| SCHEMBL5109531 | 0.78 | LMNA (0.40) | AGTR1AGTR2TBXA2RALDH1A1 | |
| SCHEMBL6303964 | 0.78 | TP53 (0.36) | TP53 | |
| SCHEMBL6298916 | 0.75 | TP53 (0.39) | AGTR1AGTR2TP53 | |
| SCHEMBL6304439 | 0.73 | GLP1R (0.39) | AGTR1AGTR2TBXA2RGLP1RALDH1A1 | |
| SCHEMBL5109571 | 0.72 | AGTR1 (0.39) | AGTR1AGTR2TBXA2RGRM5TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165557-B1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORP (US) | 2004-09-29 | — | — | EP | claimed |
| US-7348326-B2 | Heteroaryl fused aminoalkyl imidazole derivatives: selective modulators of GABAa receptors | NEUROGEN CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060160842-A1 | Heteroaryl fused aminoalkyl imidazole derivates: selective modulators of GABAA receptors | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | US | disclosed |
| US-6972293-B2 | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors | NEUROGEN CORPORATION (US) | 2005-12-06 | — | — | US | disclosed |
| EP-1165557-B1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040023993-A1 | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors | NEUROGEN CORPORATION A CORPORATION OF THE STATE OF DELAWARE (US) | 2004-02-05 | — | — | US | disclosed |
| US-6627624-B1 | Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, | NEUROGEN CORPORATION | 2003-09-30 | — | — | US | disclosed |
| US-20030092912-A1 | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa Receptors | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2003-05-15 | — | — | US | disclosed |
| US-6380210-B1 | USEFUL IN DIAGNOSIS AND TREATMENT OF ANXIETY, DOWN SYNDROME, SLEEP, COGNITIVE AND SEIZURE DISORDERS, DEPRESSION, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND ENHANCEMENT OF MEMORY AND ALERTNESS | NEUROGEN CORPORATION | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160842-A1 | Heteroaryl fused aminoalkyl imidazole derivates: selective modulators of GABAA receptors | GABRB1, GABRA1, GABRB3 | AGTR1 261/4885AGTR2 368/4885TBXA2R 190/4885 |
| US-20030092912-A1 | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa Receptors | GABRA1, GABRB1, GABRA4 | AGTR1 208/4885AGTR2 331/4885TBXA2R 274/4885 |
| US-20040023993-A1 | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors | GABRA1, GABRB1, GABRA4 | AGTR1 208/4885AGTR2 331/4885TBXA2R 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.